Transforming the Treatment of Neuromuscular Diseases
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.
Creating the new generation of genetic therapies
Advancing revolutionary therapies to treat degenerative neuromuscular diseases
Careers at PepGen
We’re seeking passionate individuals who can help us to create therapies to improve the future of people living with neuromuscular diseases
Latest Updates
PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Initiation of Phase 1 Study Marks PepGen’s Transition to a Clinical Stage Company This …
PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development
Dr. Mellion brings deep experience in neuromuscular disease research and treatment as a biopharma executive, …
PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology
BOSTON, March 30, 2022 – PepGen, Inc., advancing the next generation of oligonucleotide therapies with …